Medpace (MEDP)
(Delayed Data from NSDQ)
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$390.91 USD
+4.59 (1.19%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $390.50 -0.41 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
Medpace (MEDP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Medpace (MEDP) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 8.16% and 2.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 15.84% and -1.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Medpace (MEDP): Can Its 3.5% Jump Turn into More Strength?
by Zacks Equity Research
Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) and Dexcom Offer New Solutions for Diabetes
by Zacks Equity Research
Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.
Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 4.63% and 2.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for August 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th.
Top Ranked Momentum Stocks to Buy for August 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 26th.
Top Ranked Momentum Stocks to Buy for August 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 24th.
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for August 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 20th.
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
by Zacks Equity Research
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
The Zacks Analyst Blog Highlights: Houghton Mifflin Harcourt Company, CoreLogic, FTI Consulting, Artisan Partners Asset Management and Medpace Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Houghton Mifflin Harcourt Company, CoreLogic, FTI Consulting, Artisan Partners Asset Management and Medpace Holdings
Near-Term Outlook Tepid for Medical Services Industry
by Urmimala Biswas
This sector witnesses growing demand for telemedicine-focused online medical services amid the pandemic.
Service Side of US Economy is Up and Running: 5 Top Picks
by Tirthankar Chakraborty
The service sector index read 58.1% in July, a 17-month high. Lest we forget, a reading above 48.5% indicates expansion of the broader economy.
Bet on These 5 Low Leverage Stocks This Earnings Season
by Zacks Equity Research
Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently
3 Reasons Why Medpace (MEDP) Is a Great Growth Stock
by Zacks Equity Research
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates (Revised)
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 61.90% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 52.38% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Medpace (MEDP) This Earnings Season?
by Zacks Equity Research
Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medpace (MEDP) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.